Cargando…

Viruses and Viral Diseases

More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of human immunodeficiency virus (HIV) infections. The others have been approved for the therapy of herpesvirus (herpes simplex virus (HSV), varicella-zoster virus (VZV...

Descripción completa

Detalles Bibliográficos
Autor principal: De Clercq, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151824/
http://dx.doi.org/10.1016/B0-08-045044-X/00211-X
_version_ 1783521338249445376
author De Clercq, E.
author_facet De Clercq, E.
author_sort De Clercq, E.
collection PubMed
description More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of human immunodeficiency virus (HIV) infections. The others have been approved for the therapy of herpesvirus (herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV)), hepadnavirus (hepatitis B virus (HBV)), hepacivirus (hepatitis C virus (HCV)), and myxovirus (influenza, respiratory synctural virus (RSV)) infections. New compounds are in clinical development or under preclinical evaluation, and, again, half of these target HIV infections. Yet, quite a number of important viral pathogens (i.e., human papilloma virus (HPV), HCV, hemorrhagic fever viruses) remain in need of effective and/or improved antiviral therapies.
format Online
Article
Text
id pubmed-7151824
institution National Center for Biotechnology Information
language English
publishDate 2007
record_format MEDLINE/PubMed
spelling pubmed-71518242020-04-13 Viruses and Viral Diseases De Clercq, E. Comprehensive Medicinal Chemistry II Article More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of human immunodeficiency virus (HIV) infections. The others have been approved for the therapy of herpesvirus (herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV)), hepadnavirus (hepatitis B virus (HBV)), hepacivirus (hepatitis C virus (HCV)), and myxovirus (influenza, respiratory synctural virus (RSV)) infections. New compounds are in clinical development or under preclinical evaluation, and, again, half of these target HIV infections. Yet, quite a number of important viral pathogens (i.e., human papilloma virus (HPV), HCV, hemorrhagic fever viruses) remain in need of effective and/or improved antiviral therapies. 2007 2007-04-11 /pmc/articles/PMC7151824/ http://dx.doi.org/10.1016/B0-08-045044-X/00211-X Text en Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
De Clercq, E.
Viruses and Viral Diseases
title Viruses and Viral Diseases
title_full Viruses and Viral Diseases
title_fullStr Viruses and Viral Diseases
title_full_unstemmed Viruses and Viral Diseases
title_short Viruses and Viral Diseases
title_sort viruses and viral diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151824/
http://dx.doi.org/10.1016/B0-08-045044-X/00211-X
work_keys_str_mv AT declercqe virusesandviraldiseases